Every Form 4 that eXoZymes Inc (EXOZ) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow EXOZ and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full EXOZ filings page.
EXOZYMES INC. (EXOZ) reported that Chief Executive Officer Michael Heltzen increased his direct holdings of common stock through several transactions in August 2026. On August 25–26, 2026, he purchased a total of 855 shares in open market or private transactions at prices between $7.35 and $7.60 per share. On August 19, 2026, he also acquired 8,841 shares as a grant or award at $6.40 per share. No Rule 10b5-1 trading plan is reported for these transactions.
EXOZYMES INC. (EXOZ) reported that Chief Commercial Officer Damien Alan Perriman exercised restricted stock units into common shares. On August 19, 2026, he converted 19,612 RSUs into 19,612 shares of common stock from a January 14, 2026 grant of 62,759 RSUs. Following these transactions, he directly holds 28,499 common shares and 43,147 RSUs that continue to vest periodically.
EXOZYMES INC. (EXOZ) reported that Chief Scientific Officer Korman Tyler Paz exercised 32,964 Restricted Stock Units into 32,964 shares of Common Stock on August 19, 2026. The RSUs convert on a one-for-one basis. Following these transactions, Paz directly holds 762,837 shares of Common Stock and 46,140 RSUs (derivative securities).
EXOZYMES INC. Chief Scientific Officer Korman Tyler Paz reported small open-market sales of company common stock. On April 8, Paz sold 750 shares at an average price of $10.0406 per share, followed by another 750 shares on April 9 at $10.525 per share.
Across the two days Paz sold a total of 1,500 shares and now directly holds 729,123 shares of EXOZYMES INC. common stock. The transactions are classified as open-market sales of non-derivative common stock.
EXOZYMES INC. Chief Commercial Officer Damien Alan Perriman received equity-based compensation on April 1, 2026. He was granted stock options for 146,437 shares of common stock at an exercise price of $9.49 per share and a restricted stock award of 62,759 shares.
The restricted shares vest quarterly at 3,923 shares, with 15,689 shares vesting immediately and a final 3,917-share installment scheduled on April 1, 2029. The options vest monthly at 3,050 shares, with 36,609 shares vesting immediately and a final 3,078-share installment also on April 1, 2029.
After these awards, Perriman directly holds 62,759 common shares from the restricted stock grant and 146,437 stock options, all granted as compensation rather than through open-market buying or selling.
Perriman Damien Alan reported acquisition or exercise transactions in this Form 4 filing.
EXOZYMES INC. Chief Commercial Officer Damien Alan Perriman received a grant of 8,887 shares of common stock on 2026-04-01. The shares were awarded as a compensation-related grant at a reported price of $8.44 per share, rather than through an open-market purchase or sale.
Opgenorth Paul Hideo reported acquisition or exercise transactions in this Form 4 filing.
EXOZYMES INC. reported that Vice President of Development Paul Hideo Opgenorth received a grant of 3,999 shares of common stock on April 1, 2026 at a price of $8.44 per share. Following this compensation-related award, his direct holdings increased to 645,149 shares of EXOZYMES common stock.
Exozymes Inc. Vice President-Finance Nawaz Fouad received a stock award of 5,999 shares of common stock. The shares were granted at a value of $8.44 per share and are reported as a grant, award, or other acquisition rather than an open-market purchase. Following this award, his directly held common stock position increased to 9,488 shares.
Korman Tyler Paz reported acquisition or exercise transactions in this Form 4 filing.
Exozymes Inc. reported that Chief Scientific Officer Tyler Paz Korman received a stock grant of 5,332 shares of common stock on April 1, 2026, at a value of $8.44 per share. Following this compensation-related award, Korman directly holds a total of 730,623 common shares.